Andreas Tiede: PK-Guided Approaches for Recombinant Porcine Factor VIII in Acquired Hemophilia
Andreas Tiede, Professor in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post on LinkedIn:
“Dosing of Obizur — recombinant porcine factor VIII — can be challenging due to short half-life in bleeding patients with acquired haemophilia. You can read about our experience with PK-guided continuous infusion and bolus dosing in an upcoming JTH article.”
Read the full article here .
Title: Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A
Authors: Justus Heeg, Christiane Dobbelstein, Alfonso Iorio, Heiko Schenk, Benjamin Seeliger, Andreas Tiede
Stay updated on the latest scientific advancements with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies